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BHS Guidelines for the treatment of 
Burkitt’s lymphoma  
C. Bonnet, MD, PhD1, A. Janssens, MD, PhD2, K. L. Wu, MD, PhD3, W. Schroyens, MD, PhD4, V. Van 
Hende, MD5, P. Heimann, MD, PhD6, T. Tousseyn, MD7, M. Andre, MD8, D. Bron, MD, PhD9, A. Van Hoof, 
MD, PhD10, G. Verhoef, MD, PhD2, B. De Prijck, MD1, Y. Beguin, MD, PhD1, D. Dierickx, MD, PhD2 
Burkitt’s lymphoma is a rare but very aggressive non-Hodgkin’s lymphoma characterised by an isolated 
translocation t(8;14)(q24;q32). The sporadic form is the sub-entity most frequently encountered in Belgium. 
Diagnosis and initial work-up must be completed rapidly to start treatment as soon as possible. Positron 
emission tomography scan is useful for initial staging and to evaluate the chemosensitivity of the tumour 
during and after treatment. After debulking, it is recommended to add rituximab to chemotherapy. Currently 
intensive short-cycle and low intensity chemotherapies are two valuable options. Radiotherapy is not 
indicated except in case of central nervous system involvement. Patients achieving complete remission 
must be followed carefully during the first year to detect recurrence of the disease. More than 80% of 
patients sustain their remission one year following initial treatment and are considered cured. For patients 
in partial remission or with chemosensitive relapse, autologous stem cell transplantation is recommended 
following re-induction with non-cross-resistant polychemotherapy. Monitoring complete blood counts 
and cognitive functions is important to detect late toxicity of the applied therapies. 
(Belg J Hematol 2015;6(2):61-9)
Introduction
Burkitt’s lymphoma (BL) is a rare but very aggressive 
non-Hodgkin’s lymphoma (NHL) accounting for 0.8% 
of all B-cell lymphomas. Three different clinical sub-
types of BL are recognised: endemic BL (eBL), sporadic 
variant (sBL) and immunodeficiency-associated BL (idBL).1 
Endemic BL, the most common form of BL with a geo-
graphical distribution identical to that of Plasmodium 
falciparum, mainly affects facial bones; typically the jaw. 
In sBL, the terminal ileum, caecum and intra-abdominal 
lymph nodes are the most commonly affected sites. 
Immunodeficiency-associated BL is mainly seen in 
human immunodeficiency virus (HIV) positive patients 
and, to a lesser extent, in the context of immunomo-
dulatory drugs in transplant patients or patients with 
auto-immune disease and in patients with primary 
immunodeficiency disorders (PID).1  
Endemic BL is almost exclusively encountered in the 
paediatric population, whereas PID and transplantation-
related BL are very rare. Therefore these three subtypes 
will not be discussed in this article. 
Pathology
For the histopathological diagnosis of BL, as for all 
lymphoproliferations, a surgical excision biopsy is pre-
ferred over a fine needle aspirate cytological evaluation 
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or a core needle biopsy. However the latter two can be 
sufficient when the anatomical location is difficult to 
access or in case of recurrent disease.
BL cells are typically medium-sized lymphocytes with 
multiple small round nucleoli and little cytoplasm.1 
Their growth pattern is monotonous and diffuse, often 
with a ‘starry sky’ appearance due to a high amount of 
tingible body macrophages (Figure 1).  
BL has a characteristic immunophenotypic profile: 
CD10+, CD20+, Ki67+ in nearly 100%, TdT-, Bcl2-, 
Bcl6+, c-MYC+. The hallmark cytogenetic aberration 
involves the overexpression of c-MYC oncogene, mostly 
due to a t(8;14)(q24;q32) or less frequently a t(8;22)
(q24;q11) or t(2;8)(q24;p12) translocation, and can be 
detected in 90% of cases by classical karyotyping or 
fluorescence in situ hybridisation (FISH). Cytogenetic 
analysis is recommended to allow a clear distinction 
between BL and other c-MYC-driven B-NHL, especially 
diffuse large B-cell lymphoma. BL is mostly character-
ised by a simple karyotype including a t(8;14)(q24;q32) 
translocation with few additional abnormalities such 
as gain of chromosome 1q while other c-MYC-driven 
B-NHL will exhibit a complex karyotype with multiple 
chromosomal gains and/or losses (Table 1). Fifteen to 
thirty percent of sBL and 25-40% of idBL are EBV+, 
in contrast with eBL where >90% of cases are EBV+.1 
Microarray-based gene expression profiling can identify 
a molecular Burkitt’s signature but this is not yet used 
in daily clinical practice.2-4
The differential diagnosis with “B-cell lymphoma, un-
classifiable, with features intermediate between diffuse 
large B-cell lymphoma and Burkitt’s lymphoma”, previ-
ously named ‘Burkitt’s-like lymphoma (BLL)’ is essential 
(Table 1), as the outcome is poor with bad response to 
the classical regimens used for BL or DLBCL.1,5-8 This 
provisional histological sub-entity encompasses several 
aggressive B-cell lymphomas that do not entirely reflect 
the morphological, immunohistochemical, cytogenetic 
or clinical characteristics of a typical BL. 
Initial work-up
Staging must be completed rapidly in order to avoid 
delay of therapy, which must start within 48 hours after 
diagnosis. 
A personal history and clinical examination must be 
performed with attention to B symptoms (fever, night 
sweats and weight loss), performance status (PS) and 
neurological symptoms and signs.
Laboratory tests must include complete blood counts, 
liver and renal function, electrolytes, uric acid, lactate 
dehydrogenase (LDH) and serology for HIV, EBV, hep-
atitis B and C. 
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Figure 1. Illustration of a pathological preparation of Burkitt’s 
Lymphoma (haematoxylin and eosin, 400x). Medium-sized cells 
with slightly irregular nuclei with coarsely dispersed chromatin 
often showing several nucleoli. Presence of numerous mitoses. 
Courtesy of Dr I. Scagnol, CHU, ULG, Liège.
Figure 2. High avidity for 18FDG of BL-cells. Illustration of the 
avidity of Burkitt’s Lymphoma-cells for the 18FDG. PET scan at 
initial staging (girl, 19 years old, post transplant t(8,14)(q32;q21) 
pos BL, stage IV with elevated LDH serum level). 
Courtesy of Prof Dr O. Gheysens, UZ Leuven.
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Contrast-enhanced chest and abdominal/pelvic CT 
scans are mandatory. Although BL are 18FDG-avid 
(Figure 2), PET scan is not formally indicated in this 
situation and, in clinical practice, cannot always be 
performed immediately.9,10 A bone marrow aspiration 
with biopsy and a lumbar puncture with flow cytometry 
of the cerebrospinal fluid are mandatory. 
Before starting treatment, cardiac evaluation (transtho-
racic echocardiography), pregnancy testing in women of 
child-bearing age and discussion about fertility issues 
must be done.
Staging
Two staging systems are used: the Murphy and Hustu 
staging system and the Ann Arbor classification (Table 
2).11,12 The first has been developed for paediatric BL 
and is now also used in protocols including adolescent 
and young adults (AYAs). It takes into account the 
frequently observed extranodal involvement and in-
completely resected intra-abdominal or intra-thoracic 
masses. This staging system is not validated in adult 
BL and no comparison of the prognostic value with the 
Ann Arbor classification is available. 
Prognostic factors and treatment 
stratification
Prognostic factors used to stratify patients into different 
treatment groups vary from one co-operative group to 
another. Age, PS, LDH, bone marrow and central nervous 
system (CNS) involvement are the most frequently used.12
The LYSA-GRAALL Intergroup recognises three dif-
ferent prognostic groups. Group A comprises patients 
with completely resected stage I or abdominal stage II 
disease (Murphy and Hustu classification). Group C 
encompasses patients with CNS infiltration and/or bone 
marrow involvement. Other patients are classified as 
group B.
The Dana Farber Intergroup distinguishes two prog-
nostic groups.13 Patients with normal LDH, good PS 
(ECOG 0 or 1) and a tumour mass <10 cm are allocated 
to the low-risk group. Other patients are considered 
high-risk.
The MD Anderson Cancer Centre and the Cancer 
and Leukaemia Group B (CALGB) do not distinguish 
different prognostic groups.14,15
These stratifications determine the intensity, length and 
type of regimen (combination and number of cycles of 
systemic and intrathecal chemotherapy and the need 
for radiotherapy). However, it seems increasingly clear 




Unfortunately, given the low incidence of the disease, 
available studies include only a limited number of 
patients and published randomised studies are not 
available. Comparing studies is difficult because dis-
ease definition, stratification and median age of included 
patients vary.
Treatment must be started promptly (ideally within 
48 hours after diagnosis) including prevention of the 
tumour lysis syndrome (TLS) by forced diuresis and 
the use of rasburicase.13 The unavoidable first step of 
treatment is the application of prephase with low-dose 
cyclophosphamide (e.g. 200 mg/m²/day(d), d1-5) and 
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Table 1. Differential diagnosis between Burkitt’s lymphoma and “B-cell lymphoma, unclassifiable, with 
features intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma”.1
BL B-cell lymphoma, unclassifiable, with features 







DLBCL: diffuse large B-cell lymphoma, BL: Burkitt’s lymphoma
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prednisone (e.g. 60 mg/m²/d, d1-5). In comparison with 
standard dose of chemotherapy, the application of this 
prephase limits the risk of TLS by decreasing the re-
lease of cytokines, particularly in case of high tumour 
burden, a situation that can be lethal given the aggres-
siveness and chemosensitivity of the tumour. Moreover, 
this procedure allows finalising the staging process.
Intensive short-cycle chemotherapies (ISCC) that include 
alkylating agents such as cyclophosphamide and cell-
cycle phase-specific agents that cross the blood-brain 
barrier (i.e. cytarabine and methotrexate) are frequently 
combined but are associated with a high rate of haema-
tological and non-haematological toxicities. These regi-
mens further aim to prevent CNS extension by the 
administration of intrathecal therapy consisting of 
methotrexate, cytarabine and prednisone.14,15
Low intensity chemotherapies (LIC), such as Dose Adjust-
ed (DA)-EPOCH-R (etoposide, vincristine, cyclophos-
phamide, doxorubicin, prednisone and rituximab) or 
Short Cycle (SC)-EPOCH-R, kill tumour cells by pro-
longed low-concentration drug exposure.16 This type 
of regimen seems as efficient and less toxic compared 
to ISCC and may be more suitable for frailer patients 
(elderly or HIV+ patients). As these regimens have no 
drugs that cross the blood-brain barrier, they cannot 
be used in case of CNS involvement.
The interval between cycles of chemotherapy must be 
as short as possible and a new cycle must start as soon 
as haematological recovery has occurred. In this setting, 
the use of granulocyte-colony stimulating factors is 
essential.
Rituximab gives sufficient promising results to recom-
mend its adjunction to chemotherapy and it may even 
erase the prognostic difference between young and 
elderly patients. However, its administration is avoided 
during the debulking phase given the high risk of TLS. 
Involved-field radiotherapy has no place in BL, except 
for patients with CNS involvement. In this situation, 
either pancranial or craniospinal irradiation (in case 
of leptomeningeal disease) can be applied, taking into 
account the high neurological and myelosuppressive 
toxicity rates. The recommended dose is 40 Gy, varying 
between 36 and 45 Gy and depending on the clinical 
condition. Boost radiotherapy is possible in case of 
localised intracerebral disease. 
In case of initial CNS invasion, the number of intrathecal 
chemotherapy administrations is increased. 
Autologous stem cell transplantation (SCT) has no place 
for patients in complete response (CR) and must be 
reserved for patients in first partial response (PR) or in 
chemosensitive relapse. Due to the high proliferation rate 
of BL, graft-versus-tumour effects observed after alloge-
neic SCT are too slow to appear and to be efficient and 
therefore this type of transplant is not recommended.17,18 
Table 2. Murphy and Ann Arbor classifications.12
Reproduced from Linch D, et al. with permission.
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Recommended treatment schedules for first line treatment
Given the rarity of the disorder, it is highly recom-
mended to include patients in clinical trials conducted 
by international co-operative groups. 
Localised disease
In the rare cases of completely resected localised disease, 
a short multi-agent chemotherapy program (e.g. CO-
PADM x2) without CNS prophylaxis gives very good 
results and avoids toxicities associated with longer 
chemotherapy.19 
Disseminated disease 
Figures 3 to 6 show different treatment schedules used 
Figure 3. The LYSA-GRAAL Intergroup regimen.15 
CR: complete remission; PR: partial remission; COP: cyclophosphamide, vincristine, prednisone; R-COPADM: rituximab, cyclo-
phosphamide, vincristine, prednisone, doxorubicin, methotrexate; CYM: HD methotrexate, cytarabine; CYVE: cytarabine, etoposide; 
MAINTENANCE A: prednisone, vincristine, methotrexate, cyclophosphamide, adriamycin; MAINTENANCE B: aracytine, etoposide. 
IT²: methotrexate & solu-medrol intrathecal; IT³: methotrexate, cytarabine & solu-medrol intrathecal; *: dosage of methotrexate 
depending on age and CNS infiltration ; **: number of IT injections depending on CNS infiltration; °: dosage of cytarabine depending 
on age; °°: dosages of cytarabine and methotrexate depending on age.
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by the main co-operative groups. ISCC used by the 
LYSA-GRAAL Intergroup, the German Multicentre 
Study Group for Adult ALL (GMALL) or the Dana Farber 
Institute are very efficacious with an acceptable benefit/
toxicity ratio.15,20-22
In 2012 the LYSA-GRAAL intergroup reported the pre-
liminary results of the LMBA02 protocol (R-COPADM 
x2 and R-CY(M)VE x2). With a median follow-up of 38 
months, the 3 year EFS and OS of 128 young patients 
with HIV- BL were 76 and 82%, respectively.15 At the 
same time, the GMALL protocol reported rates of PFS 
and OS at 7 years of 83 and 88%, respectively, for 134 
BL patients younger than 85 years.20 The Dana Farber 
protocol (R-CODOX-M x2 and R-IVAC 2x) observed 
Figure 4. The GMALL/NHL protocol.14 
CR: complete remission; A: dexamethasone, vincristine, ifosfamide, HD-methotrexate, etoposide, cytarabine, intrathecal triple therapy; 
B: dexamethasone, vincristine, cyclophosphamide, HD-methotrexate, adriamycin, intrathecal triple therapy; C: dexamethasone, 
vindesine, HD-methotrexate, etoposide, HD-cytarabine; a: dexamethasone, reduced ifosfamide, reduced HD-methotrexate, 
reduced etoposide, reduced cytarabine, methotrexate intrathecal; b: dexamethasone, reduced vincristine, cyclophosphamide, 
reduced HD-methotrexate, adriamycin, methotrexate intrathecal; IT³: methotrexate, dexamethasone & cytarabine intrathecal.
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PFS and OS rates of 64.6% and 72.8%, respectively 
in a group of 60 young patients. The 2 year EFS and 
OS were 83.3 and 81.5% for low-risk patients and 59.5 
and 69.9% for high-risk patients.21 The National Cancer 
Institute (NCI) recently published promising results 
obtained with the LIC DA-EPOCH-R regimen in a 
small cohort of 19 patients. With a median follow-up of 
86 months, the PFS and OS rates were 95% and 100% 
respectively. The SC-EPOCH-RR regimen, reserved for 
HIV+ patients, was associated with PFS and OS rates 
of 90 and 100% respectively.22 To date, no direct com-
parison between ISCC and LIC is available.
Particular situations
Elderly patients
Fit elderly patients, until the age of 75, can be treated with 
the ISCC regimens as long as the doses of cytarabine 
and methotrexate are adjusted. The DA-EPOCH-R reg-
imen could be an alternative for elderly BL patients.16 
With the association of rituximab and chemotherapy, 
the worse prognosis of older patients is less apparent.12,20 
HivBL
It is recommended to use the same ISCC protocols for 
patients with hivBL.23 The SC-EPOCH-RR is alternative 
but the results need validation in a larger cohort.22 
In addition to chemotherapy, the use of highly active 
anti-retroviral therapy (HAART) has clearly improved 
response and survival rates of these patients.16,24,25 How-
ever, given the possibility of interactions between anti-
retroviral and chemotherapeutic drugs, close cooperation 
between haematologists and infectiologists is mandatory. 
Treatment recommendation BHS 
Lymphoproliferative Group
The Belgian Hematological Society (BHS) lymphopro-
liferative subcommittee recommends an ISCC regimen 
for young patients with a newly diagnosed BL. These 
regimens can also be applied in elderly patients up to the 
age of 75 who are fit, as long as the doses for cytarabine 
and methotrexate are adjusted. A LIC as DA-EPOCH-R 
can be an alternative in patients older than 75 or patients 
less than 75 with comorbidities as long as CNS involve-
ment is excluded. For HIV+ patients without important 
comorbidities, ISCC remains the first choice of treat-
ment. SC-EPOCH-R can be an alternative in patients 
with a bad PS as long as the CNS is not involved.
Re-evaluation
The BHS lymphoproliferative subcommittee recom-
mends performing a CT-scan in the middle and at the 
end of treatment. A PET scan is only indicated in case 
of residual masses.  
Follow-up
After treatment, CT-scans are repeated every six months 
during the first year. A patient with sustained CR one 
year after treatment can be considered cured and there-
fore, imaging procedures can be omitted from the second 
year on. Given the risk of late toxic effects, physicians 
must continue to follow complete blood counts and 
cognitive functions at regular intervals. 
Relapse
Usually, relapses occur during the first year following 
treatment. In patients with relapsed disease, autologous 
SCT can result in a PFS of 30-40%. Allogeneic SCT is 
also an option in relapsing patients with a sibling or 
matched related donor; however, the role of reduced 
intensity conditioning (RIC) and T-cell depletion is not 
well defined.17,18
Conclusion
Sporadic BL and hivBL are two BL subtypes encoun-
Figure 5. The DANA-Farber regimen.21,26 
aa-IPI: Age-adjusted International Prognostic Index; R: rituximab; 
CODOX-M: cyclophosphamide, doxorubicin, vincristine, meth-
otrexate; IVAC: ifosfamide, cytarabine, etoposide; IT*: cytarabine 
intrathecal; IT**: methotrexate intrathecal. 
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tered in Belgium. Although rare, BL is a very aggressive 
NHL due to its high proliferation rate. Pathological and 
cytogenetic analyses are necessary to exclude a BLL 
and staging procedures must be completed rapidly to 
avoid delay of treatment initiation. A prephase with low-
dose steroids and cyclophosphamide allows finishing 
initial staging, establishing chemosensitivity of the 
tumour and avoiding TLS. Following prephase, ‘ISCC’ 
or ‘LIC’, with the administration of rituximab leads 
to survival rates of more than 80%. However, without 
available randomised studies, it is quite difficult to 
recommend one specific therapeutic regimen above 
another and therefore it is highly recommended to enrol 
patients in clinical studies. After treatment, patients 
must be followed to detect late side effects.
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Key messages for clinical practice
1. BL, characterised by an isolated translocation t(8;14)(q24;q32), is a rare but very aggressive NHL 
due to the extremely high proliferation rate.
2. Diagnosis and staging must be completed rapidly and treatment started within 48 hours. 
3. After debulking, to avoid TLS, it is recommended to add rituximab to ISCC or LIC. Involved-field 
radiotherapy has no place in BL, except for patients with CNS involvement.
4. Patients achieving CR must be followed carefully during the first year to detect recurrence of the 
disease. More than 80% of patients sustain their remission one year following initial treatment 
and are considered cured.
5. Prolonged monitoring of complete blood counts and cognitive functions are important to detect 
late toxicity of the applied therapies. 
6. For patients in PR or with chemosensitive relapse, autologous SCT is recommended following 
re-induction with non-cross-resistant polychemotherapy. 
